Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 14Breast Neoplasms 12Neoplasms by Site 2Neoplasms 2Neoplasm Metastasis 2Breast Diseases 2Stage II Prostate Adenocarcinoma 1Skin Diseases 1Salivary Gland Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Ovarian Neoplasms 1Metastatic Neuroendocrine Prostate Cancer 1Inflammatory Breast Neoplasms 1Dementia 1Cognitive Dysfunction 1Carcinoma, Ductal, Breast 1

Interventions

pembrolizumab 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Docetaxel 3Cisplatin 3Carboplatin 3entrectinib 2Radiotherapy, Intensity-Modulated 2Platinum 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2trastuzumab deruxtecan 1luprolide acetate gel depot 1lenvatinib 1dehydroftorafur 1darolutamide 1ceralasertib 1apalutamide 1amivantamab 1X-Rays 1Surveys and Questionnaires 1Radiotherapy, Conformal 1Radiosurgery 1Pemetrexed 1Leuprolide 1Immunoglobulin G 1Gonadotropin-Releasing Hormone 1Glutamate Carboxypeptidase II 1Fluorouracil 1EBC-46 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Salivary Gland Neoplasms × Gonadotropin-Releasing Hormone × Clear all
NCT04325828 2026-05-08

YATAGARASU

Janssen Pharmaceutical K.K.

Phase 2 Active not recruiting
31 enrolled 15 charts
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡